Drug Sensitivity and Resistance Testing Platform for Personalized Medicine at the Institute for Molecular Medicine Finland (FIMM)

Video   Jun 23, 2015

 

In collaboration with research groups and the Hospital District of Helsinki and Uusimaa, we have set up drug sensitivity and resistance testing (DSRT) platform with a set of 461 approved and investigational oncology drugs on patient samples. Ex vivo drug testing is currently performed at FIMM with primary cancer cells from patients with leukemia and multiple myeloma as well as cancer cell lines. The drug sensitivity responses, measured by cell viability and death readouts, are integrated with molecular profiling such as exome sequencing, transcriptomics and phosphoproteomics. Application of the platform to AML patient samples has uncovered taxonomic drug-response subtypes and individualised therapy based on DSRT has resulted in several clinical responses. The DSRT platform enables drug repositioning, provides new combinatorial possibilities and allows for linking drug sensitivities to predictive biomarkers. We are developing the platform with additional readouts and increasing the number of drugs. Our Labcyte Access Workstation, with Echo550 and Echo525 integration, allows development and set-up of miniaturised follow-up assays, such as reverse-phase protein array and qPCR, using non-contact acoustic dispensing.

 
 
 
 

Recommended Videos

The Role of Proteogenomics in Cancer Research

Video

Proteomics is the comprehensive study of the complete set of proteins in an organism (called the proteome). Analyzing the proteome of a patient’s cancer can also provide information on how to best diagnose and treat the patient.

WATCH NOW

Contrasting LBAs and LC-MS for Peptide and Protein Bioanalysis

Video

Kelly Doering discusses ligand binding assays (LBAs) and compares the advantages and limitations of this technology to LC-MS.

WATCH NOW

Garbage In = Garbage Out: Limited Peer Review in Cannabis Sequencing

Video

Many companies are offering DNA sequencing for the cannabis field but not all of these companies have scientific staff that have published genomics papers. Do they know how to sequence? This recent review implies, in some cases, they do not.

WATCH NOW

 

Comments | 0 ADD COMMENT

Like what you just watched? You can find similar content on the communities below.

Drug Discovery Genomics Research Proteomics & Metabolomics

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE